Korro Reports KRRO-111 Preclinical Results, Expects 2027 Regulatory Submission

Korro reported preclinical results for KRRO-111, saying it may address lung and liver manifestations of alpha-1 antitrypsin deficiency. The company expects a regulatory submission in 2027.